Page results
-
Patients with an aggressive form of leukaemia will now be able to receive a breakthrough immunotherapy on the NHS which was developed and trialled at UCLH and UCL.
-
Breathing aids developed by engineers at UCL, UCLH and Mercedes-AMG High Performance Powertrains have been delivered to 40 NHS hospitals across the country.
-
On Sunday 23 November, the Royal National Orthopaedic Hospital (RNOH) successfully connected to UCLH’s Epic electronic health record (EHR). This is another milestone in our collaboration and digital transformation across North Central London.
-
Update about our hospital on Gray's Inn Road
-
UCLH has welcomed its 1000th patient to our proton beam therapy department, which opened in December 2021.
-
Information for service users about the RESPOND service for refugees and asylum seekers.
-
This easy read page offers advice for patients on managing pain after an operation.
-
This information is for UCLH patients with cancer or a blood condition who are being offered a PICC (peripherally inserted central catheter).
-
UCLH is contributing to a national priority trial of the drug ruxolitinib in patients with Covid-19 pneumonia (infection of the lungs).
-
This series of wellbeing videos have been designed to help people manage the side effects of cancer treatment.
File results
-
FOI/2022/0544 - Wards/ departments that provide services to 0-17 year-olds
-
FOI/2022/0545 - Criteria used in determining acceptance of GP referrals for osteoporosis treatment, and for priorisation of osteoporosis appointments
-
FOI/2022/0546 - Metastatic Cholangiocarcinoma (CCA) or Acute myeloid leukaemia
-
FOI/2022/0548 - Biologic and biosimilar products within Rheumatology
-
FOI/2022/0549 - SACT (systemic anti-cancer therapy) /cervical cancer treatments
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis